Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

A 14 Day Randomized, Open-Label, Cross-Over, Single Center, Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs. Divalproex Sodium Extended-Release in Child and Adolescent Patients With Epilepsy

To assess the tolerability of switching from Depakote Sprinkle Capsules or Depakote tablets to Depakote ER tablets in the pediatric population.

Inclusion Criteria:

• Male or female patient with a clinical diagnosis of epilepsy considered stable by the investigator.
• Must be in good physical health, on the same dose of all medications, including Depakote and other AEDs, for 2 week period prior to randomization.
• Minimum body weight of 37 lbs.

Exclusion Criteria:

• Six-month history of drug or alcohol abuse.
• Status epilepticus within 6 months prior to screening.
• Abnormal platelet or ALT/AST levels.